Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

IPAF should receive early treatment for sharing similar clinical characteristics as CTD-ILD: a report from 273 Chinese patients.

Clinical rheumatology·2020

Same author

New first-line treatment strategies for advanced lung squamous cell carcinoma.

Translational lung cancer research·2020

Same author

Long Noncoding RNA <i>UCA1</i> Facilitates Endometrial Cancer Development by Regulating <i>KLF5</i> and <i>RXFP1</i> Gene Expressions.

Cancer biotherapy & radiopharmaceuticals·2020

Same author

Esmolol inhibits inflammation and apoptosis in the intestinal tissue via the overexpression of NF-κB-p65 in the early stage sepsis rats.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology·2020

Same author

Studies on the interactional characterization of preheated silkworm pupae protein (SPP) with anthocyanins (C3G) and their effect on anthocyanin stability.

Food chemistry·2020

Same author

Long Noncoding RNA SCAMP1 Targets miR-137/CXCL12 Axis to Boost Cell Invasion and Angiogenesis in Ovarian Cancer.

DNA and cell biology·2020

Search research articles

Related Experiment Video

Updated: Oct 13, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

CMTM6, a potential immunotherapy target.

Jie Liang¹, Shaohua Li¹, Wei Li¹

¹Department of Immunology, Medical College of Qingdao University, No. 308 Ningxia Road, Qingdao, Shandong, 266071, People's Republic of China.

Journal of Cancer Research and Clinical Oncology

|November 16, 2021

Summary

This summary is machine-generated.

The CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) stabilizes programmed death ligand 1 (PD-L1) expression, impacting tumor immune escape. This review highlights CMTM6 as a potential immunotherapy target in various cancers.

Keywords:

CMTM6 Immunotherapy PD-L1

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Oct 13, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Programmed death ligand 1 (PD-L1) is a key immune checkpoint molecule mediating tumor immune escape.
Tumor cells utilize PD-L1 to evade the host immune system.
Understanding PD-L1 regulation is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

To review the recent research progress on CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) in various cancers.
To explore the role of CMTM6 as a novel regulator of PD-L1 expression.
To evaluate CMTM6 as a potential immunotherapy target.

Main Methods:

Literature review of studies investigating CMTM6 and PD-L1 expression.
Analysis of the molecular mechanisms by which CMTM6 affects PD-L1 stability.
Synthesis of findings from various cancer types and diseases.

Main Results:

CMTM6 binds to PD-L1 and stabilizes its expression on the cell surface.
CMTM6 prevents lysosomal degradation of PD-L1.
Elevated CMTM6 expression is linked to tumor immune escape and immunosuppression.

Conclusions:

CMTM6 is a critical regulator of PD-L1 expression and plays a significant role in tumor immune evasion.
CMTM6 represents a promising novel therapeutic target for cancer immunotherapy.
Further research is warranted to elucidate the full potential of targeting CMTM6 in diverse malignancies.